Search

N6-methyladenosine (m6A) is the most abundant mRNA modification. However, the role of m6A in regulating β-cell function is unknown. To address the functional role of METTL14, a key component of the m6A methyltransferase complex, in β-cells, we generated an METTL14 β-cell specific knockout mouse in adult MIP-CreERT transgenic mice. 4 weeks after tamoxifen treatment (100 mg/kg for 3 times every other day), the feeding glucose of βKO mice were 55.1% higher in βKO mice. βKO mice are also glucose intolerant. The AUC was increased by 54.7% in βKO mice (P<0.01). The fasting glucose were 307.5 ± 24.3 mg/dl in βKO mice and 219.0 ± 7.8 mg/dl in control mice (P<0.001). The response to insulin was similar between βKO and control mice. The feeding insulin levels in βKO mice were significantly decreased by 58.9% (P<0.01). The serum insulin levels from βKO mice were significantly lower at 0, 15 and 30 minutes after glucose challenge. In addition, the insulin secretion from βKO islets was less than 50% of control islets after incubated at 16.7 mM glucose. Surprisingly, β-cell mass in βKO mice was 55.9% higher than that in control mice (P<0.05). In addition, we did not detect β-cell death in βKO islets. However, β-cell proliferation in βKO islets was increased by 1.3-fold. To understand the molecular mechanism, we performed RNA-seq to detect the gene expression in βKO and control islets from male mice 8 weeks after tamoxifen treatment. Among 106 altered genes in βKO islets, 104 genes were upregulated (P<0.001) and 2 genes were downregulated. The genes response to ER stress such as Pdia4, Itpr1, Thbs1, Ire1α and Igfbp5 were among the top up-regulated genes. We applied m6A-seq in MIN6 cells and confirmed that Ire1α was modified by m6A in its last exon and 3' UTR region. We further showed that both mRNA and protein of Ire1α and spliced XBP-1 were significantly increased in βKO islets. In conclusion, METTL14 plays an important role in regulating insulin secretion, and METTL14 deficiency in β-cells induces diabetes by increasing ER stress. Disclosure: L. Men: None. J. Sun: None. D. Ren: None. Funding: National Institutes of Health (P30DK020595) [ABSTRACT FROM AUTHOR]

Endothelial dysfunction is an initiating key step for diabetic macrovascular complications, and it is closely related to the hemodynamic microenvironment in vivo. However, diabetic patients usually coexist with other cardiovascular risk factors, and the more powerful targeting strategy for protecting endothelium is still limited. Selenoprotein S (SelS) was found in our previous study that could increase vascular endothelial cells resistance to oxidative stress associated with protein kinase C α (PKCα). Thus, in this study, we constructed a diabetic vascular endothelial bionic microenvironment mimicking hyperglycemia and/or hyperlipidemia based on microfludic chip through modulating the concentration of medium glucose and oxidized low density lipoproteins. Our results showed that under diabetic vascular endothelial bionic microenvironment, the upregulation of SelS enhanced nitric oxide synthase (eNOS) expression and reduced endothelin-1 level in human aortic endothelial cells (HAECs), accompany with increase in cell viability and SOD1 and SOD2 activity, and decrease in ROS. Furthermore, SelS overexpression attenuated the activation of PKCα, which subsequently promoted the activation of PI3K/Akt/eNOS pathway. Conversely, the knockdown of SelS resulted in an enhancement of endothelial injury. These findings suggest that SelS could protect endothelial cells from oxidative stress injury under diabetic vascular endothelial bionic microenvironment through PKCα and PI3K/Akt/eNOS pathway. Our results offer a promising and biomimetic platform for investigation on endothelial protection, and provide evidence of SelS as potential novel target to treat diabetic macrovascular complications. Disclosure: S. Yu: None. Y. Zhong: None. L. Men: None. J. Yao: None. J. Du: None. Funding: National Natural Science Foundation of China (81570727) [ABSTRACT FROM AUTHOR]

Interleukin-8 (IL-8, also named CXCL8) binds to its receptors (CXCR1 and CXCR2) with subsequent recruitment of neutrophils and enhancement of their infiltration into inflamed sites, which exaggerates inflammation in many diseases. Recent studies have proposed that metabolic disorders can be attenuated by counteracting certain inflammatory signal pathways. In this study, we examined whether intervention with G31P, an antagonist of CXCL8, could attenuate tissue inflammation and development of metabolic disorders in db/db mice. The db/m and db/db mice were subcutaneously injected with G31P or equivalent normal saline once a day for 6 wk. The physical and metabolic parameters, glucose tolerance, insulin sensitivity, hepatic lipid accumulation, and inflammation markers were measured. G31P improved hepatic insulin sensitivity by modulating expression of genes related to gluconeogenesis and phosphorylated Akt levels. The expressions of several genes encoding proteins involved in de novo lipogenesis were decreased in G31P-treated db/db mice. Meanwhile, immune cell infiltration and cytokine release were attenuated in db/db mice with G31P treatment. G31P also improved the ratio of proinflammatory M1 and anti-inflammatory M2 macrophages. Furthermore, G31P ameliorates metabolic disturbances via inhibition of CXCR1 and CXCR2 pathways in db/db mice. These data suggest that the selective inhibition of CXC chemokines may have therapeutic effects on symptoms associated with obesity and diabetes.

Background: The mechanisms underlying diabetic encephalopathy are largely unknown, and no effective treatments are available. Catalpol has received much attention due to its numerous biological effects, especially in neuroprotective studies. The aim of this study was to investigate the effects of catalpol on cognitive functions in diabetic rats and the underlying mechanisms., Methods: A rat model of diabetes was established by streptozotocin injection, followed by intraperitoneal infusion of catalpol after 10 weeks. Two weeks later, the Morris water maze was used to test the spatial learning performance. Nissl staining was performed to evaluate the morphological changes in the hippocampus. Expression of protein kinase Cγ (PKCγ) and caveolin-1 (Cav-1) in the hippocampus were assessed by reverse transcription PCR and Western blotting. Activities of anti-oxidative enzymes such as glutathione (GSH), superoxide dismutase (SOD) and catalase (CAT) and levels of malonaldehyde (MDA) were measured using commercial kits., Results: Significant hippocampal neuronal injury was observed in rats with streptozotocin-induced diabetes. Moreover, cognitive dysfunction was associated with markedly increased oxidative stress in the brain. Catalpol treatment significantly attenuated cognitive deficits, neuronal damage, and oxidative stress in the brain of diabetic rats. Biochemical analyses showed that catalpol reversed the down-regulation of PKCγ and Cav-1 expression in the diabetic rats., Conclusions: Spatial memory in diabetic rats is associated with the expression of PKCγ and Cav-1. Catalpol treatment markedly attenuated oxidative stress, reversed the alteration of PKCγ, Cav-1 and spatial memory deficits.